# A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

> **NCT04634409** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1755 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Bamlanivimab
- **DRUG:** Etesevimab
- **DRUG:** Placebo
- **DRUG:** VIR-7831
- **DRUG:** Bebtelovimab

## Key facts

- **NCT ID:** NCT04634409
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2021-07-27
- **Final completion:** 2021-10-18
- **Target enrollment:** 1755 (ACTUAL)
- **Last updated:** 2022-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04634409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04634409, "A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04634409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*